Yahoo Finance

Interim analysis of 1-level BAGUERA®C IDE study meets threshold for non-inferiority

Geneva, March 11, 2025 – Spineart, a fast-growing company in spine surgery innovation, today announces that it has completed a planned interim analysis for its 1-level BAGUERA®C IDE study, which ...
WDAF-TV

SPINEART COMPLETES ENROLLMENT IN THE BAGUERA®C IDE TRIAL FOR TWO-LEVEL CERVICAL DISC REPLACEMENT

GENEVA, March 8, 2024 /PRNewswire/ -- Spineart SA, manufacturer of the BAGUERA ® C Cervical Disc Prosthesis, today announced it has completed enrollment in its U.S. IDE trial studying the BAGUERA ® C ...
Yahoo Finance

INTERIM ANALYSIS OF 2-LEVEL BAGUERA® C IDE STUDY MEETS THRESHOLD FOR NON-INFERIORITY

Last month, Spineart announced that its interim analysis for its 1-level BAGUERA ® C IDE study had also showed that BAGUERA ® C had met the threshold for a non-inferiority claim against the study ...
WIVB-TV

SPINEART COMPLETES ENROLLMENT IN THE BAGUERA®C IDE TRIAL FOR SINGLE-LEVEL CERVICAL DISC REPLACEMENT

GENEVA, Feb. 29, 2024 /PRNewswire/ -- Spineart SA, manufacturer of the BAGUERA®C Cervical Disc Prosthesis, is delighted to announce completion of enrollment in its U.S. IDE trial studying the ...